TY - JOUR
T1 - Strong antihyperglycemic effects of water-soluble fraction of Brazilian propolis and its bioactive constituent, 3,4,5-tri-O-caffeoylquinic acid
AU - Matsui, Toshiro
AU - Ebuchi, Sumi
AU - Fujise, Tomoko
AU - Abesundara, Kanthi J.M.
AU - Doi, Shima
AU - Yamada, Hideo
AU - Matsumoto, Kiyoshi
PY - 2004/11/1
Y1 - 2004/11/1
N2 - To clarify the suppression of postprandial blood glucose rise via α-glucosidase (AGH) inhibitory action by natural compounds, propolis was examined in this study. A single oral administration of propolis extract (50% methanol fraction on XAD-2 column chromatography) in Sprague-Dawley rats demonstrated a potent antihyperglycemic effect with the significant AUC 0-120 min reduction of 38% at a dose of 20 mg/kg compared to that of controls. Among the active compounds isolated from the fraction, 3,4,5-tri-caffeoylquinic acid was found to be a prominent candidate that exerts the effect and shows a strong maltase-specific inhibition with an IC 50 value of 24 μM. In addition, the noncompetitive inhibition power apparently increased with the number of caffeoyl groups bound to quinic acid.
AB - To clarify the suppression of postprandial blood glucose rise via α-glucosidase (AGH) inhibitory action by natural compounds, propolis was examined in this study. A single oral administration of propolis extract (50% methanol fraction on XAD-2 column chromatography) in Sprague-Dawley rats demonstrated a potent antihyperglycemic effect with the significant AUC 0-120 min reduction of 38% at a dose of 20 mg/kg compared to that of controls. Among the active compounds isolated from the fraction, 3,4,5-tri-caffeoylquinic acid was found to be a prominent candidate that exerts the effect and shows a strong maltase-specific inhibition with an IC 50 value of 24 μM. In addition, the noncompetitive inhibition power apparently increased with the number of caffeoyl groups bound to quinic acid.
UR - http://www.scopus.com/inward/record.url?scp=22044456421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=22044456421&partnerID=8YFLogxK
U2 - 10.1248/bpb.27.1797
DO - 10.1248/bpb.27.1797
M3 - Article
C2 - 15516726
AN - SCOPUS:22044456421
SN - 0918-6158
VL - 27
SP - 1797
EP - 1803
JO - Biological and Pharmaceutical Bulletin
JF - Biological and Pharmaceutical Bulletin
IS - 11
ER -